Informativeness of laboratory indicators as predictors of the course and outcomes of coronavirus infection

Objective - to assess the informativeness of laboratory parameters as predictors of the course and outcomes of coronavirus infection. Material and methods. A retrospective analysis of clinical cases of severe coronavirus infection was carried out in 64 patients who were hospitalized in the intensive care unit of the Kursk Regional Infectious Diseases Clinical Hospital named after N.A. Semashko from January to December 2021 Based on the outcome of the disease (recovery or death), all patients were divided into two groups. The first group with recovery included 37 patients, the second group with death included 27 patients. The study of laboratory parameters was carried out over time upon admission before the start of biological therapy with Olokizumab and on the 10th day of hospital stay. For statistical processing and analysis of relationships, calculations were carried out using parametric (Pearson’s correlation coefficient - R_xy), non-parametric (Spearman’s rank correlation coefficient - R_s) methods, as well as factor analysis using a correlation matrix. All calculations were carried out using the STATISTICA version 10 software package. Results. Analysis of the study results showed that in patients of the first group, during treatment, there was a decrease in indicators of inflammation and the blood coagulation system, while in the second group there was a negative dynamics of these same indicators, which was combined with the progression of the inflammatory reaction and coagulation factors. Conclusion. Many years of experience in studying the new coronavirus infection have made it possible to identify the main predictors of severe forms of the disease, which make it possible to predict the course and outcomes of Covid-19. According to our data, the most significant criteria determining an unfavorable outcome of the disease was a tendency to increase initially high levels of CRP, IL-6, ferritin, which was combined with the progression of lymphopenia. Also a key prognostic factor is D-dimer, the level of which, according to our study, increased in group 2 by 2.5-3 times.

1. Nikiforov V.V., Suranova T.G., Chernobrovkina T.Ya., Yanko skaya Ya.D., Burova S.V. New coronavirus infection (COVID-19): clinical and epidemiological aspects. The Russian Archives of Internal Medicine. 2020;10(2): 87-93 (in Russ.). DOI 10.20514/2226-6704-2020-10-2-87-93. EDN: MELBOP.

2. Badalyan K.R., Solovyeva EIu. COVID-19: long-term health impacts. Consilium Medicum. 2021;23(12):993-999. (in Russ.). DOI: 10.26442/20751753.2021.12.201347. EDN: JKGAQE.

3. Huang C., Huang L., Wang Y., Li X., Ren L., Gu X., Kang L., Guo L., et al. 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study. Lancet. 2023;401(10393):e21-e33. DOI: 10.1016/S0140-6736(23)00810-3.

4. Lombardo M.D.M., Foppiani A., Peretti G.M., Mangiavini L., Battezzati A., Bertoli S., Martinelli Boneschi F., Zuccotti G.V. Long-Term Coronavirus Disease 2019 Complications in Inpatients and Outpatients: A One-Year Follow-up Cohort Study. Open Forum Infect Dis. 2021;8(8):ofab384. DOI: 10.1093/ofid/ofab384.

5. Sayganov S.A., Mazurov V.I., Bakulin I.G., Latariya E.L., Artyushkin S.A., Chizhova O.Yu., Ruslyakova I.A., Prokof'eva N.A., et al. Clinical course, effectiveness of therapy and outcomes of new coronavirus infection: preliminary analysis. Herald of North-Western State Medical University named after I.I. Mechnikov. 2020;12(2):27-38 (in Russ.). DOI: 10.17816/mechnikov34932. EDN: LQZNNL.

6. Gudima G.O., Khaitov R.M., Kudlay D.A., Khaitov M.R. Molecular immunological aspects of diagnosis, prevention and treatment of coronavirus infection. Immunologiya. 2021;42(3):198-210 (in Russ.). DOI: 10.33029/0206-4952-2021-42-3-198-210. EDN: UKOQDZ.

7. Ustyantseva I.M., Zinchenko M.A., Guselnikova Yu.A., Kulagina E.A., Aliev A.R., Agadzhanyan V.V. SARS-CoV-2. Markers of inflammation. Polytrauma. 2020;(4):35-43 (in Russ.). DOI: 10.24411/1819-1495-2020-10044. EDN: TGGCOF.

8. Khostelidi S.N., Zaytsev V.A., Vartanyan S.A., Nikitin N.A., Evtukh G.N., Gilalov M.N., Portnov G.V., Zubareva A.A., et al. Mucormycosis in patients with COVID-19 in Russia: the results of a prospective multi-center study. Journal Infectology. 2022;14(2): 116-127 (in Russ.). DOI: 10.22625/2072-6732-2022-14-2-116-127. EDN: DOHCVF.

9. Abdulamir A.S., Hafidh R.R. The Possible Immunological Pathways for the Variable Immunopathogenesis of COVID-19 Infections among Healthy Adults, Elderly and Children. Electronic Journal of General Medicine. 2020;17(4):em202. DOI: 10.29333/ejgm/7850.

10. Henderson L.A., Canna S.W., Schulert G.S., Volpi S., Lee P.Y., Kernan K.F., Caricchio R., Mahmud S., et al. On the Alert for Cytokine Storm: Immunopathology in COVID-19. Arthritis Rheumatol. 2020;72(7): 1059-1063. DOI 10.1002/art.41285.

11. Frolova E.V., Filippova L.V., Uchevatkina A.E., Ponomarenko V.A., Borzova Y.V., Shurpitskaya O.A., Taraskina A.E., Gaikovaya L.B., et al. Immunological features of patients with COVID-19 depending on the severity of the disease. Problems in Medical Mycology. 2021;23(1):3-13 (in Russ.). DOI 10.24412/1999-6780-2021-1-3-13. EDN: JLYVNQ.

12. Han H., Yang L., Liu R., Liu F., Wu K.L., Li J., Liu X.H., Zhu C.L. Prominent changes in blood coagulation of patients with SARS-CoV-2 infection. Clin Chem Lab Med. 2020;58(7):1116-1120. DOI: 10.1515/cclm-2020-0188.

13. Lodigiani C., Iapichino G., Carenzo L., Cecconi M, Ferrazzi P., Sebastian T., Kucher N., Studt J.D., et al. Venous and arterial thromboembolic complications in COVID-19 patients admitted to an academic hospital in Milan, Italy. Thromb Res. 2020;191:9-14. DOI: 10.1016/j.thromres.2020.04.024.

14. Tang N., Li D., Wang X., Sun Z. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. Journal of Thrombosis and Haemostasis. 2020;18(4):844-847. DOI: 10.1111/jth.14768.

15. Kampf G., Todt D., Pfaender S., Steinmann E. Persistence of coronaviruses on inanimate surfaces and their inactivation with biocidal agents. Journal of Hospital Infection. 2020;104(3):246-251. DOI: 10.1016/j.jhin.2020.01.022.

16. Alserehi H., Wali G., Alshukairi A., Alraddadi B. Impact of Middle East respiratory syndrome coronavirus (MERS-CoV) on pregnancy and perinatal outcome. BMC Infectious Diseases. 2016;16:105-108. DOI: 10.1186/s12879-016-1437-y.

17. Gusev D.A., Vashukova M.A., Fedunyak I.P. Experience of using a recombinant humanized monoclonal antibody to the human interleukin-6 receptor in patients with COVID-19. Journal Infectology. 2020;12(3):28-33 (in Russ.). DOI 10.22625/2072-6732-2020-12-3-28-33. EDN: NHOZHP.

18. Valishin D.A., Murzabaeva R.T., Galimov R.R., Galieva A.T., Galieva R.A., Shaykhullina L.R., Burganova A.N., Gumerova R.Z., et al. Main criteria for determining the tactics of managing patients with the new coronavirus infection COVID-19. Medical Bulletin of Bashkortostan. 2021;16(1):61-66 (in Russ.). EDN: FOZTMA.

19. Zadumina D.N., Skvortsov V.V. Changes in hematological parameters during COVID-19. Lechaschi Vrach. 2022;1(11):30-36 (in Russ.). DOI: 10.51793/OS.2022.25.11.005. EDN: YSCHZT.

20. Tian S., Xiong Y., Liu H., Niu L., Guo J., Liao M., Xiao S.Y. Pathological study of the 2019 novel coronavirus disease (COVID-19) through postmortem core biopsies. Mod Pathol. 2020;33(6):1007-1014. DOI: 10.1038/s41379-020-0536-x.

21. Vertkin A.L., Shishkova V.N., Sycheva A.S., Kebina A.L., Nosova A.V., Uryanskaya K.A., Gazikova H.M., Zav'yalov G.V. The possibilities of metabolic support in coronavirus infection. Terapiia. 2020;7(41):68-76 i Russ.). DOI: 10.18565/therapy.2020.7.146-155. EDN: RWWHDO.